Trade with Eva : Analytics in action: ATHA

Showing posts with label ATHA. Show all posts

Wednesday, June 7, 2023

Notable purchases -- CEO/10% owner adds to ZUMZ; notable sales -- CEO active in ALTR

Buyers:

ATHA Chief Financial Officer and Chief Business Officer bought 65,012 shares at $2.85 - $3.02 worth ~$192K.
DE Director bought 675 shares at $ $370.57 - $371.38 worth ~$250K.
FCPT President and CEO bought 7,600 shares at $26.05 - $26.08 worth ~$198K.
ISTR Director bought 10,000 shares at $11.25 - $11.57 worth ~$114K.
PRAA Director bought 7,425 shares at $20.16 - $20.20 worth ~$150K.
ZUMZ CEO/10% owner and President - International bought a total of 84,930 shares at $13.22 - $14.67 worth ~$1.1 mln.

Sellers:

The results indicated Athira's lead drug, ATH-1017, also called fosgonimeton, didn't have a statistically significant impact on working memory processing speed or cognition when compared with a placebo after 26 weeks.

Mark Litton, Athira's CEO, says the company is in a "fortuitous situation" despite the disappointing results.